The Life Sciences team advised Shanghai Argo Biopharmaceutical Co., Ltd. on its two exclusive license and collaboration agreements with Novartis.
Argo will receive upfront payments of $185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales. Novartis will receive an ex-Greater China exclusive license for a Phase 1/2a stage cardiovascular asset, a worldwide exclusive license for a Phase 1 stage cardiovascular asset as well as an option to license compounds directed against up to two cardiovascular targets.
Founded in April 2021, Argo is a privately held biotechnology company based in Shanghai.
The Goodwin team was led by Wenseng “Wendy” Pan and consisted of Kevin Guan, Longfei Fang and Elliot Horlick, with invaluable assistance from Arman Oruc, Charlie Stewart, Kevin Walsh, Cathy McCarty, Susan Lee, Huiya Wu, Barry Bazian and Dan Karelitz.
For more details, read the press release and coverage in BioSpace, Endpoints News and Fierce Biotech.